Dose-finding study of kratom alkaloids pilot
Ended Definitive Contract Awarded Last action
- Contract number
- 75F40121C00199
- Awardee
-
Altasciences Clinical Kansas Inc. UEI WZ5RGEMMQ3W9
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $2,370,057
Award facts
- Opportunity
-
- RFPFDA1238584 Solicitation number
- Contract value 100% obligated
- $2,370,057.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Silver Spring, MD 20903, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $25,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,345,057 |
About this award
Altasciences Clinical Kansas Inc., a clinical research organization specializing in pharmaceutical and pharmacological studies, was awarded a $2.37M firm fixed-price definitive contract by the Food and Drug Administration (FDA) for a dose-finding study of kratom alkaloids pilot. The contract, awarded on September 30, 2021, with performance to be completed by March 30, 2025, was not set aside for small businesses. Work will be performed in Silver Spring, Maryland. As a child entity within a larger corporate structure, Altasciences Clinical Kansas brings extensive expertise in conducting complex clinical trials, particularly in substance use disorder research and pharmacological investigations.
This contract exemplifies the FDA's investment in rigorous pharmacological research for botanical compounds. Altasciences Clinical Kansas holds a substantial track record with federal agencies, including a $21M indefinite delivery contract with the National Institute on Drug Abuse (NIDA) focused on pharmacokinetic and pharmacodynamic trials supporting medication development for substance use disorders. The company's portfolio demonstrates consistent competitiveness in the open market, having been awarded multiple prime contracts from both NIDA and the FDA for specialized clinical trials, indicating strong capability in designing and executing detailed safety, tolerability, and efficacy studies for investigational agents and botanical substances.
Quick answers
Who was awarded contract 75F40121C00199?
75F40121C00199 was awarded to Altasciences Clinical Kansas Inc. by Food and Drug Administration (Department of Health and Human Services) on September 30, 2021.
How much is contract 75F40121C00199 worth?
The government has obligated $2,370,057 on 75F40121C00199.
Was contract 75F40121C00199 competed?
The extent of competition for 75F40121C00199 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award